CORTISPORIN OINTMENT Rx
Generic Name and Formulations:
Hydrocortisone 1%, polymyxin B (as sulfate) 5000 Units/g, neomycin (as sulfate) 0.35%, bacitracin (as zinc) 400 Units/g.
Indications for CORTISPORIN OINTMENT:
Short-term use in corticosteroid-responsive dermatoses with secondary infection.
Apply sparingly and massage in 2–4 times daily.
Do not use in eyes, external ear canal if eardrum perforated. Tuberculous, fungal, or viral lesions.
Intertrigo, diaper or stasis dermatitis or ulceration, extensive burns (neomycin may be absorbed). Avoid prolonged use or on large areas. Use lowest effective dose. Monitor for HPA axis suppression; avoid abrupt cessation if used for chronic conditions. Discontinue if infection persists or worsens or if superinfection occurs. Occlusion: not recommended. Pregnancy (Cat.C). Nursing mothers.
Steroid + antibiotics.
Local irritation, folliculitis, hypertrichosis, dermatitis, sensitization, ototoxicity, nephrotoxicity (if neomycin is significantly absorbed), HPA axis suppression (esp. in children), epidermal and dermal atrophy (esp. in thin-skinned or occluded areas).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma